Hutchinson-Gilford progeria syndrome (HGPS) is a rare progeroid disorder, featured with premature skin wrinkling, lack of skin elasticity, absence of subcutaneous fat, alopecia, atherosclerosis and ...
Sentynl will obtain full rights to Progerinin after specified milestones, while immediately collaborating with PRG S&T to accelerate clinical development for HGPS. Progerinin is designed to inhibit ...
Children who develop deep wrinkles, stunted growth, and rapidly aging bones and blood vessels as early as 1 to 2 years of age may be suffering from Hutchinson-Gilford Progeria Syndrome (HGPS), a rare ...
Children who develop deep wrinkles, stunted growth, and rapidly aging bones and blood vessels as early as 1 to 2 years of age may be suffering from Hutchinson-Gilford Progeria Syndrome (HGPS), a rare ...
Sentynl will acquire full rights to the investigational drug candidate, Progerinin (SLC-D011), adding to its commercial portfolio of rare and ultra-rare disease products AHMEDABAD, India and SOLANA ...
Sentynl, a Zydus Group company, receives worldwide proprietary rights to Zokinvy, adding to portfolio of biopharmaceuticals for rare and ultra-rare diseases Zokinvy is approved in the U.S. (2020), ...
Hutchinson-Gilford progeria syndrome (HGPS), an extremely rare genetic disorder, arises when a silent point mutation in the gene encoding the nuclear envelope protein lamin A, LMNA, leads to abnormal ...
Geroscience examines the underlying biology of aging to delay chronic diseases and extend the healthy years of human life.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results